Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ECE1 | P42892 | 2/20 | 0.55 |
| ▸ | MME | P08473 | 6/20 | 0.53 |
| ▸ | ACE | P12821 | 4/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CTH | P32929 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (Isobutyrylamino)Acetic Acid SCHEMBL622544 | 0.82 | ALDH1A1 (0.67) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL22807661 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL13429289 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL1644159 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL6307075 | 0.80 | ALDH1A1 (0.64) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL5853497 | 0.79 | — | — | |
| SCHEMBL23880757 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL17037463 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| Tiopronin SCHEMBL3009491 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTLMNAPTGS2TDP1 | |
| SCHEMBL3008983 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MAPTLMNAPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444388-B | Method for preparing morpholine-2, 5-dione monomer by polylactic acid ammonolysis | 中国科学院青岛生物能源与过程研究所 | 2024-06-14 | — | — | CN | claimed |
| CN-116444388-A | Method for preparing morpholine-2, 5-dione monomer by polylactic acid ammonolysis | 中国科学院青岛生物能源与过程研究所 | 2023-07-18 | — | — | CN | claimed |
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | claimed |
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1263747-B1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2004-11-24 | — | — | EP | claimed |
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | ALBIREO AB (SE) | 2003-09-04 | — | — | US | claimed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | claimed |
| CN-116444388-B | Method for preparing morpholine-2, 5-dione monomer by polylactic acid ammonolysis | 中国科学院青岛生物能源与过程研究所 | 2024-06-14 | — | — | CN | disclosed |
| CN-116444388-B | Method for preparing morpholine-2, 5-dione monomer by polylactic acid ammonolysis | 中国科学院青岛生物能源与过程研究所 | 2024-06-14 | — | — | CN | disclosed |
| CN-116444388-A | Method for preparing morpholine-2, 5-dione monomer by polylactic acid ammonolysis | 中国科学院青岛生物能源与过程研究所 | 2023-07-18 | — | — | CN | disclosed |
| CN-116444388-A | Method for preparing morpholine-2, 5-dione monomer by polylactic acid ammonolysis | 中国科学院青岛生物能源与过程研究所 | 2023-07-18 | — | — | CN | disclosed |
| US-6906058-B2 | 1,5-Benzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2005-06-14 | — | — | US | disclosed |
| EP-0804181-A4 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES INC (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2001066533-A1 | 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |
| US-5952384-A | CONTACTING THE MAMMALIAN CELL WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTS OF PYRUVATE AND PYRUVATE PRECURSOR CAPABLE OF REDUCING UNDESIRED INFLAMMATORY RESPONSE AND IS ANTIOXIDANT | CELLULAR SCIENCES, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5939459-A | CONTACTING WITH AN INFLAMMATORY MEDIATOR SELECTED FROM THE GROUP CONSISTING OF PYRUVATE AND A PYRUVATE PRECURSOR AND IS PRESENT IN AN AMOUNT CAPABLE OF REDUCING THE UNDESIRED INFLAMMATORY RESPONSE AND IS AN ANTIOXIDANT | CELLULAR SCIENCES INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5798388-A | ANTIOXIDANT, ANTIASTHMA, ADMINISTERING PYRUVATE WITHOUT ALBUTEROL | CELLULAR SCIENCES, INC. (US) | 1998-08-25 | — | — | US | disclosed |
| EP-0804181-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | Cellular Sciences, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997010818-A1 | METHOD AND COMPOSITION FOR TREATING MAMMALIAN DISEASES CAUSED BY INFLAMMATORY RESPONSE | CELLULAR SCIENCES, INC. (US) | 1997-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166927-A1 | 1,5-Benzothiazepines and their use as hypolipidaemics | SLC10A2, SLC10A1, LCAT | ALDH1A1 811/4885MAPT 1147/4885LMNA 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.